Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosite and MedImmune join forces:

This article was originally published in Clinica

Executive Summary

Under an agreement that will last for up to three years, Biosite plans to use its Omniclonal phage display technology to evaluate the diagnostic potential of drug targets that will be provided by MedImmune. In addition to gaining certain diagnostic rights, Biosite will receive development fees upon delivery to MedImmune of target-specific antibodies. MedImmune expects to use Biosite's high affinity antibodies in its discovery research, which focuses on infectious disease, autoimmune disease and cancer, the company says.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts